Genetic Testing in Pediatric Epilepsy

Current Neurology and Neuroscience Reports

Volumn 17, Issue 5, 2017, Pages

  Sands, Tristan T ^a   Choi, Hyunmi ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

Genetic epilepsy; Genetic testing; Pediatric; Whole exome sequencing

Indexed keywords

MITOCHONDRIAL DNA;

ARX GENE; CDKL5 GENE; COMORBIDITY; COPY NUMBER VARIATION; CYTOGENETICS; DISEASE SEVERITY; DNA FRAGMENTATION; DNA REPLICATION; EPILEPSY; FLNA GENE; GENE; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC SCREENING; GENETIC VARIABILITY; HEMIZYGOSITY; HETEROZYGOSITY; HUMAN; KCNQ2 GENE; MERRF SYNDROME; NEXT GENERATION SEQUENCING; OUTCOME ASSESSMENT; PCDH19 GENE; PEDIATRICS; PHENOTYPE; REVIEW; SCN1A GENE; SINGLE NUCLEOTIDE POLYMORPHISM; TSC1 GENE; TSC2 GENE; WHOLE EXOME SEQUENCING; CHILD; GENETICS; HIGH THROUGHPUT SEQUENCING; PROCEDURES; STATISTICS AND NUMERICAL DATA; UTILIZATION;

CHILD; EPILEPSY; GENETIC TESTING; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; PEDIATRICS; PHENOTYPE;

EID: 85017565681     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-017-0753-y     Document Type: Review

References (69)

1. Hildebrand MS, Dahl HH, Damiano JA, Smith RJ, Scheffer IE, Berkovic SF. Recent advances in the molecular genetics of epilepsy. J Med Genet. 2013;50:271–9.
2. Salm M, Abbate K, Appelbaum P, et al. Use of genetic tests among neurologists and psychiatrists: knowledge, attitudes, behaviors, and needs for training. J Genet Couns. 2014;23:156–63.
3. Ferraro L, Pollard JR, Helbig I. Attitudes toward epilepsy genetics testing among adult and pediatric epileptologists-results of a Q-PULSE Survey. Epilepsy Curr. 2016;16:46–7.
4. Peljto AL, Barker-Cummings C, Vasoli VM, et al. Familial risk of epilepsy: a population-based study. Brain. 2014;137:795–805.
5. Berkovic SF, Howell RA, Hay DA, Hopper JL. Epilepsies in twins: genetics of the major epilepsy syndromes. Ann Neurol. 1998;43:435–45.
6. Kjeldsen MJ, Corey LA, Christensen K, Friis ML. Epileptic seizures and syndromes in twins: the importance of genetic factors. Epilepsy Res. 2003;55:137–46.
7. Berkovic SF, Mulley JC, Scheffer IE, Petrou S. Human epilepsies: interaction of genetic and acquired factors. Trends Neurosci. 2006;29:391–7.
8. Heron SE, Dibbens LM. Role of PRRT2 in common paroxysmal neurological disorders: a gene with remarkable pleiotropy. J Med Genet. 2013;50:133–9.
9. Wallace RH, Scheffer IE, Barnett S, et al. Neuronal sodium-channel alpha1-subunit mutations in generalized epilepsy with febrile seizures plus. Am J Hum Genet. 2001;68:859–65.
10. Claes L, Del-Favero J, Ceulemans B, Lagae L, Van Broeckhoven C, De Jonghe P. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am J Hum Genet. 2001;68:1327–32.
11. Singh R, Andermann E, Whitehouse WP, et al. Severe myoclonic epilepsy of infancy: extended spectrum of GEFS+? Epilepsia. 2001;42:837–44.
12. Biervert C, Schroeder BC, Kubisch C, et al. A potassium channel mutation in neonatal human epilepsy. Science. 1998;279:403–6.
13. Charlier C, Singh NA, Ryan SG, et al. A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family. Nat Genet. 1998;18:53–5.
14. Singh NA, Charlier C, Stauffer D, et al. A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nat Genet. 1998;18:25–9.
15. Weckhuysen S, Mandelstam S, Suls A, et al. KCNQ2 encephalopathy: emerging phenotype of a neonatal epileptic encephalopathy. Ann Neurol. 2012;71:15–25.
16. Weckhuysen S, Ivanovic V, Hendrickx R, et al. Extending the KCNQ2 encephalopathy spectrum: clinical and neuroimaging findings in 17 patients. Neurology. 2013;81:1697–703.
17. Poduri A, Evrony GD, Cai X, Walsh CA. Somatic mutation, genomic variation, and neurological disease. Science. 2013;341:1237758.
18. Poduri A, Pomeroy SL. Tracking the fate of cells in health and disease. N Engl J Med. 2016;375:2494–6.
19. Depienne C, Trouillard O, Bouteiller D, et al. Mutations and deletions in PCDH19 account for various familial or isolated epilepsies in females. Hum Mutat. 2010;32:E1959–75.
20. Plecko B. Pyridoxine and pyridoxalphosphate-dependent epilepsies. Handb Clin Neurol. 2013;113:1811–7.
21. van Karnebeek CD, Jaggumantri S. Current treatment and management of pyridoxine-dependent epilepsy. Curr Treat Options Neurol. 2015;17:335.
22. Epi KC, Allen AS, et al. De novo mutations in epileptic encephalopathies. Nature. 2013;501:217–21.
23. Brockmann K, Wang D, Korenke CG, et al. Autosomal dominant glut-1 deficiency syndrome and familial epilepsy. Ann Neurol. 2001;50:476–85.
24. Wang D, Pascual JM, De Vivo D. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. Glucose transporter type 1 deficiency syndrome. Seattle: GeneReviews(R); 1993.
25. DiMauro S, Hirano M. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. MERRF. Seattle: GeneReviews(R); 1993.
26. Redon R, Ishikawa S, Fitch KR, et al. Global variation in copy number in the human genome. Nature. 2006;444:444–54.
27. Wang JW, Kurahashi H, Ishii A, et al. Microchromosomal deletions involving SCN1A and adjacent genes in severe myoclonic epilepsy in infancy. Epilepsia. 2008;49:1528–34.
28. Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia. 2010;51:676–85.
29. Helbig I, Mefford HC, Sharp AJ, et al. 15q13.3 microdeletions increase risk of idiopathic generalized epilepsy. Nat Genet. 2009;41:160–2.
30. Dibbens LM, Mullen S, Helbig I, et al. Familial and sporadic 15q13.3 microdeletions in idiopathic generalized epilepsy: precedent for disorders with complex inheritance. Hum Mol Genet. 2009;18:3626–31.
31. de Kovel CG, Trucks H, Helbig I, et al. Recurrent microdeletions at 15q11.2 and 16p13.11 predispose to idiopathic generalized epilepsies. Brain. 2010;133:23–32.
32. Mefford HC, Muhle H, Ostertag P, et al. Genome-wide copy number variation in epilepsy: novel susceptibility loci in idiopathic generalized and focal epilepsies. PLoS Genet. 2010;6:e1000962.
33. Heinzen EL, Radtke RA, Urban TJ, et al. Rare deletions at 16p13.11 predispose to a diverse spectrum of sporadic epilepsy syndromes. Am J Hum Genet. 2010;86:707–18.
34. Helbig I. Genetic causes of generalized epilepsies. Semin Neurol. 2015;35:288–92.
35. Kc E, Epilepsy Phenome/Genome P. Ultra-rare genetic variation in common epilepsies: a case-control sequencing study. Lancet Neurol. 2017;16:135–43.
36. International League Against Epilepsy Consortium on Complex Epilepsies. Electronic address e-auea. Genetic determinants of common epilepsies: a meta-analysis of genome-wide association studies. Lancet Neurol. 2014;13:893–903.
37. • Ottman R, Hirose S, Jain S, et al. Genetic testing in the epilepsies–report of the ILAE Genetics Commission. Epilepsia. 2010;51:655–70. Discussion of how to weigh the risks and benefits of offering genetic testing.
38. Caraballo RH, Fontana E, Darra F, et al. Migrating focal seizures in infancy: analysis of the electroclinical patterns in 17 patients. J Child Neurol. 2008;23:497–506.
39. Shostak S, Zarhin D, Ottman R. What’s at stake? Genetic information from the perspective of people with epilepsy and their family members. Soc Sci Med. 2011;73:645–54.
40. Klein KM, Yendle SC, Harvey AS, et al. A distinctive seizure type in patients with CDKL5 mutations: hypermotor-tonic-spasms sequence. Neurology. 2011;76:1436–8.
41. Sands TT, Balestri M, Bellini G, et al. Rapid and safe response to low-dose carbamazepine in neonatal epilepsy. Epilepsia. 2016;57:2019–30.
42. Helbig I, Tayoun AA. Understanding genotypes and phenotypes in epileptic encephalopathies. Mol Syndromol. 2016;7:172–81.
43. Suls A, Mullen SA, Weber YG, et al. Early-onset absence epilepsy caused by mutations in the glucose transporter GLUT1. Ann Neurol. 2009;66:415–9.
44. • Biesecker LG, Green RC. Diagnostic clinical genome and exome sequencing. N Engl J Med. 2014;370:2418–25. This review articulates well many technical features of next generaltion sequencing.
45. Rehm HL. Disease-targeted sequencing: a cornerstone in the clinic. Nat Rev Genet. 2013;14:295–300.
46. Buiting K, Williams C, Horsthemke B. Angelman syndrome–insights into a rare neurogenetic disorder. Nat Rev Neurol. 2016;12:584–93.
47. Ramsden SC, Clayton-Smith J, Birch R, Buiting K. Practice guidelines for the molecular analysis of Prader-Willi and Angelman syndromes. BMC Med Genet. 2010;11:70.
48. Thomas RH, Berkovic SF. The hidden genetics of epilepsy-a clinically important new paradigm. Nat Rev Neurol. 2014;10:283–92.
49. Dammann O, Ferriero D, Gressens P. Neonatal encephalopathy or hypoxic-ischemic encephalopathy? Appropriate terminology matters. Pediatr Res. 2011;70:1–2.
50. Gould DB, Phalan FC, Breedveld GJ, et al. Mutations in Col4a1 cause perinatal cerebral hemorrhage and porencephaly. Science. 2005;308:1167–71.
51. Moller RS, Larsen LH, Johannesen KM, et al. Gene panel testing in epileptic encephalopathies and familial epilepsies. Mol Syndromol. 2016;7:210–9.
52. Trump N, McTague A, Brittain H, et al. Improving diagnosis and broadening the phenotypes in early-onset seizure and severe developmental delay disorders through gene panel analysis. J Med Genet. 2016;53:310–7.
53. Helbig KL, Farwell Hagman KD, Shinde DN, et al. Diagnostic exome sequencing provides a molecular diagnosis for a significant proportion of patients with epilepsy. Genet Med. 2016;18:898–905.
54. EuroEPINOMICS-RES Consortium, Epilepsy Phenome/Genome Project, Epi4k Consortium. De novo mutations in synaptic transmission genes including DNM1 cause epileptic encephalopathies. Am J Hum Genet. 2014;95:360–70.
55. Mefford HC, Yendle SC, Hsu C, et al. Rare copy number variants are an important cause of epileptic encephalopathies. Ann Neurol. 2011;70:974–85.
56. Bartnik M, Szczepanik E, Derwinska K, et al. Application of array comparative genomic hybridization in 102 patients with epilepsy and additional neurodevelopmental disorders. Am J Med Genet B Neuropsychiatr Genet. 2012;159B:760–71.
57. Olson H, Shen Y, Avallone J, et al. Copy number variation plays an important role in clinical epilepsy. Ann Neurol. 2014;75:943–58.
58. Epilepsy Phenome/Genome Project Epi KC. Copy number variant analysis from exome data in 349 patients with epileptic encephalopathy. Ann Neurol. 2015;78:323–8.
59. Ezugha H, Anderson CE, Marks HG, Khurana D, Legido A, Valencia I. Microarray analysis in children with developmental disorder or epilepsy. Pediatr Neurol. 2010;43:391–4.
60. • Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–24. Guidelines on how to weigh the evidence for pathogenicity of a variant in a known disease gene.
61. • Smith LA, Ullmann JF, Olson HE, et al. A model program for translational medicine in epilepsy genetics. J Child Neurol. 2017; doi:10.1177/0883073816685654. Description of the value a specialized clinic for genetic epilepsy can provide to epilepsy patients and referring neurologists.
62. Mefford HC, Zemel M, Geraghty E, et al. Intragenic deletions of ALDH7A1 in pyridoxine-dependent epilepsy caused by Alu-Alu recombination. Neurology. 2015;85:756–62.
63. Djemie T, Weckhuysen S, von Spiczak S, et al. Pitfalls in genetic testing: the story of missed SCN1A mutations. Mol Genet Genomic Med. 2016;4:457–64.
64. Jamuar SS, Lam AT, Kircher M, et al. Somatic mutations in cerebral cortical malformations. N Engl J Med. 2014;371:733–43.
65. Friedman E, Efrat N, Soussan-Gutman L, et al. Low-level constitutional mosaicism of a de novoBRCA1 gene mutation. Br J Cancer. 2015;112:765–8.
66. Wou K, Levy B, Wapner RJ. Chromosomal microarrays for the prenatal detection of microdeletions and microduplications. Clin Lab Med. 2016;36:261–76.
67. Campbell IM, Yuan B, Robberecht C, et al. Parental somatic mosaicism is underrecognized and influences recurrence risk of genomic disorders. Am J Hum Genet. 2014;95:173–82.
68. Green RC, Berg JS, Grody WW, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med. 2013;15:565–74.
69. • Kalia SS, Adelman K, Bale SJ, et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. Genet Med. 2016;19(2):249–55. Current recommendations and the list of reportable genes for incidental variants.